Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regorafenib

FDA-approved product (tablet, oral), marketed as Regorafenib, Stivarga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

    NCT06902246 · start 2026-08-01

    Registered record
    Registry ID
    NCT06902246
    Conditions
    Unresectable Hepatocellular Carcinoma; Hepatocellular Carcinoma
    Interventions
    Regorafenib; TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2026-08-01
    Completion
    2031-08-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnresectable Hepatocellular Carcinoma; Hepatocellular Carcinoma
    InterventionRegorafenib; TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
    PhasePhase 2
    Registry statusWithdrawn

  • Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients

    NCT07514455 · start 2026-03-15

    Registered record
    Registry ID
    NCT07514455
    Conditions
    Carcinoma, Hepatocellular; Hepatic Insufficien; Disease Progression; Treatment Failure
    Interventions
    Regorafenib (BAY 73-4506)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-15
    Completion
    2028-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular; Hepatic Insufficien; Disease Progression; Treatment Failure
    InterventionRegorafenib (BAY 73-4506)
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

    NCT06283134 · start 2026-03

    Registered record
    Registry ID
    NCT06283134
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    BioTTT001 hepatic artery infusion; toripalimab; regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    InterventionBioTTT001 hepatic artery infusion; toripalimab; regorafenib
    PhasePhase 1
    Registry statusNot yet recruiting

  • JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

    NCT07384377 · start 2026-02-06

    Registered record
    Registry ID
    NCT07384377
    Conditions
    HER2-positive Colorectal Cancer
    Interventions
    JSKN003; Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-02-06
    Completion
    2028-06-15
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Colorectal Cancer
    InterventionJSKN003; Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

    NCT07328009 · start 2026-01-19

    Registered record
    Registry ID
    NCT07328009
    Conditions
    Hepato Cellular Carcinoma (HCC)
    Interventions
    Lenvatinib; Regorafenib (BAY 73-4506); Tislelizumab+TKI; HAIC+TKI; HAIC + Tislelizumab+TKI; QL1706+TKI; HAIC + QL1706+TKI; TUDCA + Camrelizumab+TKI; XELOX + QL1706+TKI; XELOX + Tislelizumab+TKI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-19
    Completion
    2029-01-15
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepato Cellular Carcinoma (HCC)
    InterventionLenvatinib; Regorafenib (BAY 73-4506); Tislelizumab+TKI; HAIC+TKI +6 more
    PhasePhase 2
    Registry statusRecruiting

  • STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

    NCT07213570 · start 2025-10-16

    Registered record
    Registry ID
    NCT07213570
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    standard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-16
    Completion
    2027-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    Interventionstandard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506)
    PhasePhase 2
    Registry statusRecruiting

  • Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma

    NCT07148427 · start 2025-09-20

    Registered record
    Registry ID
    NCT07148427
    Conditions
    Gastric/Gastroesophageal Junction Adenocarcinoma
    Interventions
    Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-09-20
    Completion
    2028-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric/Gastroesophageal Junction Adenocarcinoma
    InterventionIparomlimab and Tuvonralimab combination with regorafenib and chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

    NCT07137390 · start 2025-09-03

    Registered record
    Registry ID
    NCT07137390
    Conditions
    Colorectal Cancer
    Interventions
    Regorafenib; Lorigerlimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2025-09-03
    Completion
    2026-01-22
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionRegorafenib; Lorigerlimab
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

    NCT06841172 · start 2025-07-21

    Registered record
    Registry ID
    NCT06841172
    Conditions
    OligoProgressive Metastatic Disease; Hepatocellular Carcinoma (HCC); Radiotherapy; Systemic Therapy
    Interventions
    radiotherapy; Systemic therapy (Continuation of current first-line systemic therapy); Systemic therapy (Early switch to second-line systemic therapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-07-21
    Completion
    2028-07-01
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOligoProgressive Metastatic Disease; Hepatocellular Carcinoma (HCC); Radiotherapy; Systemic Therapy
    Interventionradiotherapy; Systemic therapy (Continuation of current first-line systemic therapy); Systemic therapy (Early switch to second-line systemic therapy)
    PhasePhase 3
    Registry statusRecruiting

  • Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

    NCT06454409 · start 2025-05-21

    Registered record
    Registry ID
    NCT06454409
    Conditions
    Myelodysplastic Syndrome/Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome
    Interventions
    Azacitidine; Biospecimen Collection; Bone Marrow Aspiration; Regorafenib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2025-05-21
    Completion
    2030-09-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndrome/Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia +1 more
    InterventionAzacitidine; Biospecimen Collection; Bone Marrow Aspiration; Regorafenib +1 more
    PhasePhase 1
    Registry statusSuspended

  • GIST Oral Paclitaxel(Liporaxel)

    NCT06326346 · start 2024-11-20

    Registered record
    Registry ID
    NCT06326346
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Liporaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-20
    Completion
    2027-03-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionLiporaxel
    PhasePhase 2
    Registry statusRecruiting

  • Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

    NCT06087263 · start 2024-06-18

    Registered record
    Registry ID
    NCT06087263
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-06-18
    Completion
    2034-07-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionRegorafenib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

    NCT06283303 · start 2024-04-02

    Registered record
    Registry ID
    NCT06283303
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    T3011 hepatic artery infusion; toripalimab; regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-04-02
    Completion
    2025-11-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    InterventionT3011 hepatic artery infusion; toripalimab; regorafenib
    PhasePhase 1
    Registry statusUnknown

  • A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

    NCT06205732 · start 2024-01-01

    Registered record
    Registry ID
    NCT06205732
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Immunotherapy, targeted therapy.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2024-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionImmunotherapy, targeted therapy.
    PhaseNot recorded
    Registry statusUnknown

  • A Study of JMT101 in Patients With Metastatic Colorectal Cancer

    NCT06089330 · start 2024-01

    Registered record
    Registry ID
    NCT06089330
    Conditions
    Metastatic Colorectal Cancer (mCRC)
    Interventions
    JMT101; SG001; Irinotecan; Regorafenib (Stivarga)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-01
    Completion
    2024-12
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer (mCRC)
    InterventionJMT101; SG001; Irinotecan; Regorafenib (Stivarga)
    PhasePhase 2
    Registry statusUnknown